Development
Biogen Inc.
BIIB
$138.60
$3.662.71%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -61.89% | -48.97% | 29.40% | 115.98% | 95.80% |
| Total Depreciation and Amortization | -4.55% | -11.03% | -13.85% | -7.69% | 6.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 141.84% | 135.06% | -227.06% | -199.84% | -174.11% |
| Change in Net Operating Assets | 27.14% | -669.84% | -2,289.93% | 50.59% | -511.89% |
| Cash from Operations | 11.77% | -43.29% | -43.81% | -44.68% | -61.97% |
| Capital Expenditure | -15.27% | -45.11% | -50.27% | -11.46% | 6.90% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 151.32% | 147.90% | -322.51% | 201.56% | 469.88% |
| Cash from Investing | -360.12% | -323.66% | 41.69% | 210.86% | 379.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 19.19% | 84.05% | -- | -143,071.43% | -489.53% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | 80.00% | 37.50% | 58.33% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -875.51% | -323.08% | -338.34% | 81.20% | 104.22% |
| Cash from Financing | 108.54% | 145.55% | -7.17% | -34.64% | 16.24% |
| Foreign Exchange rate Adjustments | 163.02% | 139.22% | 127.55% | 27.35% | 6.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -304.63% | -165.03% | -103.18% | 116.04% | 24.48% |